Trial Profile
Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jan 2018
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 10 Dec 2014 New trial record